A practical reference on clinical development: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
== Pathways == The protein C pathways are the specific chemical reactions that control the level of expression of APC and its activity in the body. Protein C is pleiotropic, with two main classes of functions: anticoagulation and cytoprotection (its direct effect on cells). Which function protein C performs depends on whether or not APC remains bound to EPCR after it is activated; the anticoagulative effects of APC occur when it does not. In this case, protein C functions as an anticoagulant by irreversibly proteolytically inactivating Factor Va and Factor VIIIa, turning them into Factor Vi and Factor VIIIi respectively. When still bound to EPCR, activated protein C performs its cytoprotective effects, acting on the effector substrate PAR-1, protease-activated receptor-1. To a degree, APC's anticoagulant properties are independent of its cytoprotective ones, in that expression of one pathway is not affected by the existence of the other. The activity of protein C may be down-regulated by reducing the amount either of available thrombomodulin or of EPCR. This may be done by inflammatory cytokines, such as interleukin-1β (IL-1β ) and tumor necrosis factor-α (TNF-α). Activated leukocytes release these inflammatory mediators during inflammation, inhibiting the creation of both thrombomodulin and EPCR, and inducing their shedding from the endothelial surface. Both of these actions down-regulate protein C activation. Thrombin itself may also have an effect on the levels of EPCR.
Thermoresponsive polymer chains in solution adopt an expanded coil conformation. At the phase separation temperature they collapse to form compact globuli. This process can be observed directly by methods of static and dynamic light scattering. The drop in viscosity can be indirectly observed. When mechanisms which reduce surface tension are absent, the globules aggregate, subsequently causing turbidity and the formation of visible particles.
Pseudouridine was also detected in the Leishmania donovani genome. 18 pseudouridine modification sites were detected in the peptidyl transferase entry site and in the mRNA entry tunnel in protein translation. These modifications in the parasite lead to increased protein synthesis and growth rate. Pseudouridine in rRNA and tRNA has been shown to fine-tune and stabilize the regional structure and help maintain their functions in mRNA decoding, ribosome assembly, processing and translation. Pseudouridine in snRNA has been shown to enhance spliceosomal RNA-pre-mRNA interaction to facilitate splicing regulation.
{\displaystyle {\begin{aligned}&{\frac {\mathbf {D} m}{\mathbf {Dt} }}=\iiint \limits _{V}\left({\frac {\mathbf {D} \rho }{\mathbf {Dt} }}+\rho (\nabla \cdot \mathbf {u} )\right)\,dV\\[5pt]&{\frac {\mathbf {D} \rho }{\mathbf {Dt} }}+\rho (\nabla \cdot \mathbf {u} )={\frac {\partial \rho }{\partial t}}+(\nabla \rho )\cdot \mathbf {u} +\rho (\nabla \cdot \mathbf {u} )={\frac {\partial \rho }{\partial t}}+\nabla \cdot (\rho \mathbf {u} )=0\end{aligned}}}
Sources: en.wikipedia.org
Numerous beetles in the Nicrophorus genus are obligately necrophagous, for example Nicrophorus americanus and N. vespilloides. Many other beetles are facultative necrophages including checkered beetles, dermestid beetles, diving beetles, scarab beetles, silphine beetles and water scavenger beetles. Types of carrion eaten include wildlife, livestock and poultry carcasses, livestock viscera and human bodies.
== Purpose == The primary objectives of PMKSY are to attract investments in irrigation system at field level, develop and expand cultivable land in the country, enhance ranch water use in order to minimize wastage of water, enhance crop per drop by implementing water-saving technologies and precision irrigation. The plan additionally calls for bringing ministries, offices, organizations, research and financial institutions occupied with creation and recycling of water under one platform so that an exhaustive and holistic outlook of the whole water cycle is considered. The goal is to open the doors for optimal water budgeting in all sectors. Tagline for PMKSY is "more crop per drop". The Integrated Watershed Management programme was subsumed into the current PMKSY on 26 October 2015. The core implementation activities of IWMP were unchanged and were as per the Common Guidelines 2008 (Revised 2011) of IWMP. Convergence with other Central and State Government schemes, remains the top of the agenda for the programme towards optimal and judicious utilization of financial resources. Action has also been taken to undertake Natural Resources Management activities by utilizing labour component of MGNREGS and to undertake some of the Entry Point Activities in convergence with Swachh Bharat Mission (Gramin).
During the Medellín Cartel's war against the Colombian government, both the Norte del Valle Cartel and Cali Cartel formed and operated a vigilante group called Los Pepes (which also comprised members of the Colombian government, police and former members of the Medellín Cartel) to bring about the downfall of Pablo Escobar; they did so by bombing the properties of the Medellín Cartel and kidnapping, torturing and killing Escobar's associates as well as working alongside the Search Bloc, which would eventually lead to the dismantling of the Medellín Cartel and the death of Pablo Escobar. Because of the high levels of corruption, the Oficina de Envigado would do things to help the police and vice versa, to the point where the police and the cartel would sometimes do operations together against other criminals; additionally the leaders of La Oficina would often act as judges to mediate disputes between the various different drug gangs throughout Colombia, which according to some helped prevented a lot of disputes from turning violent. On Somalia coastline many people rely on fishing for economic survival, because of this Somali pirates are often known to attack foreign vessels who partake in illegal fishing and overfishing in their waters and vessels that illegally dump waste into their waters. As a result, marine biologists say that the local fishery is recovering.
For example, it has been shown that IPF patients who have a specific genotype in the mucin MUC5B gene polymorphism (see above) experience slower decline in FVC and significantly improved survival. Even if such data are interesting from a scientific point of view, the application in the clinical routine of a prognostic model based on specific genotypes is still not possible.
Ojos Locos (pronounced [ˈo.xos ˈlo.kos], Spanish for "Crazy Eyes") was founded in 2010 by restaurateurs Randy DeWitt, Jack Gibbons, Rich Hicks, and Todd East. DeWitt, the owner of parent company Front Burner Restaurants, had previously founded Twin Peaks, a chain of wilderness lodge-themed breastaurants, in 2005. The 2010 opening of the first Ojos Locos restaurant in Dallas coincided closely with the 2010 FIFA World Cup and the chain has consistently emphasized soccer as a principal sport to watch at its locations. Ojos Locos has been called a "Mexican Hooters" or "Twin Peaks for a Hispanic customer base" and markets itself to working class Hispanic men. Workers at the chain frequently speak both Spanish and English and The New York Times has singled out the restaurant as an example of an establishment that has thrived even during an anti-Spanish-language political environment. D Magazine cited it as being the best sports bar in Dallas in 2013. The servers at Ojos Locos are known as "chicas" and wear short skirts along with cleavage and midriff-baring outfits, leading the chain to colloquially be referred to as a "breastaurant". The food served is a mix of Mexican and Southwestern American food developed by chef John Franke, with tacos being a particular specialty. They are also known for their tall beer pitchers called "balones" that contain 100 US fluid ounces (3.0 L). As of 2020, there were thirteen locations across Texas, Arizona, and New Mexico.
Sources: en.wikipedia.org
== Chemical properties == According to food chemist Udo Pollmer of the European Institute of Food and Nutrition Sciences in Munich, alcohol can be absorbed in cyclodextrins, a synthetic carbohydrate derivative. In this way, encapsuled in small capsules, the fluid can be handled as a powder. The cyclodextrins can absorb an estimated 60 percent of their own weight in alcohol. A US patent was registered for the process as early as 1974.
== Diagnosis == The most reliable method of identifying hypoglycemia is through identifying Whipple's triad. The components of Whipple's triad are a blood sugar level below 70 mg/dL (3.9 mmol/L), symptoms related to low blood sugar, and improvement of symptoms when blood sugar is restored to normal. Identifying Whipple's triad in a patient helps to avoid unnecessary diagnostic testing and decreases healthcare costs. In those with a history of diabetes treated with insulin, glinides, or sulfonylurea, who demonstrate Whipple's triad, it is reasonable to assume the cause of hypoglycemia is due to insulin, glinides, or sulfonylurea use. In those without a history of diabetes with hypoglycemia, further diagnostic testing is necessary to identify the cause. Testing, during an episode of hypoglycemia, should include the following:
On average, in adult males, levels of testosterone are about seven to eight times as great as in adult females. As the metabolism of testosterone in males is more pronounced, the daily production is about 20 times greater in men. Females are also more sensitive to the hormone. In addition to its role as a natural hormone, testosterone is used as a medication to treat hypogonadism and breast cancer. Since testosterone levels decrease as men age, testosterone is sometimes used in older men to counteract this deficiency. It is also used illicitly to enhance physique and performance, for instance in athletes. The World Anti-Doping Agency lists it as S1 Anabolic agent substance "prohibited at all times".
She gained information about nine people, including the names of four of those killed, and found that some of "the dead men had indeed been running drugs but were not narco-terrorists ... or leaders of a cartel or gang". People interviewed by Garcia Cano said most of those killed were first-time crew members, and that they "included a fisherman, a motorcycle taxi driver, laborers and two low-level career criminals ... One was a well-known local crime leader who had agreed to work for narcotics smugglers." One reportedly trafficked both drugs and humans. Two unidentified bodies suspected by locals to be casualties from the 1 September strike washed up on the shores of Trinidad and Tobago, showing signs of having been blown up. People who knew him claimed one of the bodies was a Venezuelan, recognizable by his watch; the Associated Press report said "he had been jailed by Venezuelan authorities on human-trafficking charges after a boat he had operated capsized in December 2020" and people had described him as "a longtime local crime boss [who] made most of his living smuggling drugs and people across borders". Two days after the 6 November 2025 strike, a boat matching the one in the video of the strike washed ashore in the Guajira Peninsula of northwestern Colombia, near the Gulf of Venezuela, followed by bodies and charred debris, according to The New York Times. Two bodies that washed ashore were later buried by locals but, due to the remoteness of the area, did not come to media attention until the 29 December Times report.
== Diseases in aquatic animals == Bacillus cereus group bacteria, notably B. cereus and B. thuringiensis, are also pathogenic to multiple aquatic organisms including Chinese softshell turtle (Pelodiscus sinensis), causing infection characterized by gross lesions such as hepatic congestion and enlarged spleen with high mortality.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.